Daily Stock Opinions and Ratings

Opinions

Jason Snipe, CIO, Odyssey Capital Advisors Ishares Nasdaq Biotechnology IBB-Q BUY Feb 26, 2025

He likes big pharma with AbbVie his favourite name. Pipelines are starting to fill, and if rates hold and R&D gets cheaper, these stocks will continue to work.

Jason Snipe, CIO, Odyssey Capital Advisors

Owned

Unlock Rating

$137.480

Stock price when the opinion was issued

E.T.F.'s

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

(A Top Pick Jul 09/20, Up 14%) Still likes it, but took profits as the valuation was getting expensive, plus the shift from growth to value. Long term, lots of tailwinds.

BUY ON WEAKNESS

IBB gives him exposure to Moderna, its largest holding, and yet there's no single-company risk here. Biotechs have been under a lot of pressure this year, so he sees an opportunity (past of the pressure has been from shorting) if you're patient. He likes the future of biotech.

DON'T BUY

IBB vs. XLV XLV has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.

WATCH

He sold IBB last month, though he owns a lot of Regeneron (for its fundamentals) in the biotech space. You need to own individual names, not the macro in biotechs. But he could re-enter IBB when the time is right.

BUY

He likes biotech, focusing on longevity research. Better than owning a single biotech stock where you can lose 80% just on negative research findings. It's completely random--you have no idea what the outcome will be on these biotech products. Might as well own IBB and lessen risk.

BUY

The IBB has never had two down years in a row, except this and last year. It's having its best month since June 2021.

HOLD

He bought this, expecting biotech to break out, but it's been deeply disappointing. It hasn't worked yet.

BUY

The sector has been up. It makes sense because biotechs do well as rates fall; these companies finance long-duration trials then marketing.

BUY

He prefers to own individual names, but you need to own biotech, especially if there's a change in Washington (less regulation). It's very sensitive to interest rates, which will likely decline.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jason Snipe, CIO, Odyssey Capital Advisors Ishares Nasdaq Biotechnology IBB-Q BUY Feb 26, 2025

You might be interested:

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Ishares Nasdaq Biotechnology(IBB-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

David Burrows

Larry Berman CFA, CMT, CTA

Stockchase Insights

Jim Cramer - Mad Money

Mike Philbrick